Compare ATNM & CCG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATNM | CCG |
|---|---|---|
| Founded | 2000 | 2014 |
| Country | United States | China |
| Employees | N/A | 469 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.7M | 30.8M |
| IPO Year | 2013 | N/A |
| Metric | ATNM | CCG |
|---|---|---|
| Price | $0.80 | $14.20 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 1 |
| Target Price | $4.50 | ★ $350.00 |
| AVG Volume (30 Days) | ★ 94.4K | 43.0K |
| Earning Date | 05-06-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.17 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $90,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $567.38 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 11.11 | N/A |
| 52 Week Low | $0.74 | $0.34 |
| 52 Week High | $1.81 | $16.83 |
| Indicator | ATNM | CCG |
|---|---|---|
| Relative Strength Index (RSI) | 33.55 | 68.98 |
| Support Level | N/A | $0.67 |
| Resistance Level | $1.38 | $16.83 |
| Average True Range (ATR) | 0.04 | 1.97 |
| MACD | -0.00 | 0.13 |
| Stochastic Oscillator | 28.05 | 46.76 |
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.
Cheche Group Inc is engaged in the operation of providing insurance transaction services, Software-as-a-Service (SaaS) services, and other services in China. It is China's independent technology-empowered platform for auto insurance transaction services by digital auto insurance transaction premiums and insurance technology companies. The company has reshaped the traditional auto insurance distribution and services value chain to create a digital platform by improving operational efficiencies, reducing transaction costs, and expanding distribution channels. Its business scope ranges from digital insurance transactions, SaaS platforms for insurance intermediaries, AI-driven insurance pricing and underwriting services, auto insurance services for new energy vehicle (NEV) manufacturers, etc.